Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk of Recurrence in 1 cm Breast Tumors

A look at rates by subtypes

No significant differences were detected in recurrence free survival between women who received chemotherapy and those who did not among women with triple negative breast cancer (TNBC) or within any other breast cancer subtypes, in a study of 437 women diagnosed with T1a/T1b N0 breast cancer with a median follow-up of 6.2 years. Other details of the study include:

• Chemotherapy was administered more often to younger women, and to women with high grade, HER2+ or TN breast cancers.

• Recurrence free survival did not different significantly between TNBC and ER+ breast cancer (HR, 0.33).

Citation: Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG. Analysis of risk of recurrence by subtype in ≤1 cm breast tumors. [Published online ahead of print November 5, 2015]. Clin Breast Cancer. doi: 10.1016/j.clbc.2015.10.001.